T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) has emerged as a promising target for co-inhibition with PD-1/PD-L1 in cancer immunotherapy [10]. Here, PDCD1 is linked to cancer.